Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.
Drug Discov Today
; 18(13-14): 637-43, 2013 Jul.
Article
em En
| MEDLINE
| ID: mdl-23579167
ABSTRACT
In the 1990s there was a tremendous mood of optimism among pharmaceutical scientists that identification of disease-associated variations in the human genome would result in a surge of new drug targets (the 'gene-to-drug' mantra). To date the expected deluge of new drugs has not arrived. However, a small number of drugs arising directly from the study of rare human disorders showing Mendelian inheritance are now entering late stage clinical trials. Here we describe the advantages of this approach and discuss the background and early clinical trial findings with antibodies directed at a target identified in this way.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Marcadores Genéticos
/
Hiperostose
/
Sindactilia
/
Proteínas Morfogenéticas Ósseas
/
Conservadores da Densidade Óssea
/
Descoberta de Drogas
/
Terapia de Alvo Molecular
/
Anticorpos
/
Mutação
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Drug Discov Today
Assunto da revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Reino Unido